Skip to main
AARD

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 11%
Hold 33%
Sell 11%
Strong Sell 0%

Bulls say

Aardvark Therapeutics is a promising biotechnology company that is well-positioned to succeed with its lead candidate, ARD-101, in Phase 3 development for the treatment of hyperphagia associated with PWS. They also have a diverse pipeline including ARD-201, which has the potential to address current limitations of obesity treatments. However, the current clinical hold on the ARD-101 program is a major factor in our Neutral rating.

Bears say

Aardvark Therapeutics is currently facing numerous risks, including potential failure to lift the current clinical hold on ARD-101, negative clinical results from the Phase 3 HERO trial in PWS subjects, and potential partnership and geopolitical risks, which could greatly impact its financials. Additionally, the company's current valuation and price target of $6 per share seems overly optimistic and could be at risk of revision based on downwardly revised probabilities of approval for ARD-101. Overall, until Aardvark Therapeutics can address these risks and demonstrate positive clinical results, it is recommended to maintain a neutral position on the stock.

AARD has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 11% recommend Buy, 33% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 9 analysts, AARD has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.